In July 2026, Today the healthcare industry is hugely inclined towards smart packaging. Advanced packaging helps the industry to act as a source of clinical intelligence. Advanced technologies such as embedded sensors, radio-frequency identification (RFID) tags, near-field communication (NFC) chips, and connected blister systems are useful in the case of investigational drug assessment. It also helps researchers to understand whether trial data reflects true performance or participant behavior.
Smart packaging is emerging as a need for pharmaceutical companies and researchers, because study participant adherence is one of the persistent challenges in clinical research. Participants may miss doses, may perform inconsistently with the investigational drug, and may also misinterpret dosing instructions. Traditional adherence helps to measure diaries and pill counts, which may provide incomplete or imprecise information. Hence, it is unclear whether the therapy failed due to the investigational drug or because it was not taken as intended according to the protocol. Smart packaging helps to fill this gap.
Smart packaging helps the healthcare industry to automatically record when an investigational drug is accessed and whether dosing aligns with protocol requirements. Smart blister packs embedded with sensors and NFC technology can detect dose removal events and transmit data to secure digital systems. It helps to lower the need for self-reporting objectives and helps to turn the direction towards time-stamped records of medication access.
Examples include platforms such as MEMS-based solutions from AARDEX Group and Med-ic® smart blister systems from Information Mediary Corporation, which have been used in clinical research settings to monitor adherence patterns and support data analysis. These systems log dosing events, allowing researchers to compare clinical outcomes against observed investigational drug-use behavior rather than estimated adherence.
RFID-enabled packaging systems assign unique digital identities to drug packages, supporting serialization, supply chain traceability, and authentication. Such capabilities intersect with clinical trial monitoring in decentralized study designs. Such systems also allow investigators to identify adherence issues earlier in a study, rather than only discovering them during the final analysis.
One of the major contributions of smart packaging involves the interpretability of clinical trial data. Smart packaging helps to address poor adherence that may distort outcomes by providing a clearer link between dosing patterns and outcomes. For example, if a participant reports worsening symptoms but packaging data shows repeated missed doses, researchers can better contextualize whether the investigational drug itself is responsible.
With the help of smart packaging, researchers can also monitor adherence trends during the study and respond more quickly in case of an issue. Industry groups such as Thermo Fisher Scientific’s clinical research services have highlighted the role of connected technologies in improving adherence visibility and strengthening data reliability across distributed study populations. Serialization and digital tracking systems, inclusive of those used in global supply chain platforms such as Körber, support traceability and product integrity across increasingly complex trial networks.
Smart packaging helps researchers to distinguish between drug performance and participant behavior, clinical trials become more stable, more efficient, and often safer. Earlier identification of missed doses helps to improve patient monitoring and also enables timely intervention when adherence issues emerge. The technology also strengthens confidence in efficacy and safety findings, supporting more reliable regulatory and development decisions.
Companies such as Takeda have emphasized the importance of digital, participant-centered trial designs that reduce burden while improving engagement and retention.
Key benefits of smart packaging include:
The Food and Drug Administration’s Drug Supply Chain Security Act (DSCSA) continues to drive adoption of serialized, traceable, and digitally enabled packaging systems across manufacturers, distributors, and dispensers, supporting broader transparency and supply chain security.
Clinical trials nowadays are gaining importance for technologies that are now expanding into mainstream healthcare.
Connected packaging systems are already appearing in applications such as:
Some systems easily integrate with mobile apps and wearable devices to deliver reminders, adherence alerts, and patient-provider communication tools. The Proteus Digital Health system, developed in partnership with Otsuka Pharmaceutical, takes technology further by using an ingestible sensor that activates in the stomach and transmits a signal to a wearable patch, enabling confirmation of ingestion rather than dispensing alone.
Smart packaging is surely redefining the role of packaging in clinical research and healthcare delivery. Smart packaging is helping to reduce uncertainty around adherence, improve data reliability, and also strengthen confidence in study outcomes. It can also be stated that it is shifting the packaging industry from a passive container into an active data layer within the clinical evidence ecosystem.
31 July 2026
30 July 2026
30 July 2026
30 July 2026